In Silico Screening of Available Drugs Targeting Non-Small Cell Lung Cancer Targets: A Drug Repurposing Approach

The RAS–RAF–MEK–ERK pathway plays a key role in malevolent cell progression in many tumors. The high structural complexity in the upstream kinases limits the treatment progress. Thus, MEK inhibition is a promising strategy since it is easy to inhibit and is a gatekeeper for the many malignant effect...

詳細記述

書誌詳細

主要な著者:	Muthu Kumar Thirunavukkarasu, Utid Suriya, Thanyada Rungrotmongkol, Ramanathan Karuppasamy
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2021-12-01
シリーズ:	Pharmaceutics
主題:	drug-repositioning MEK inhibitor MM/GBSA Glide docking MD simulation MM/PBSA
オンライン･アクセス:	https://www.mdpi.com/1999-4923/14/1/59
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!